---
title: "After the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses… — 瑞銀 — DecisionGateway"
description: "statement by 瑞銀, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1e751-3034-7cb6-8adc-d678204a44df"
meta:
  "og:description": "statement by 瑞銀, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "After the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses… — 瑞銀 — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statement

# **After the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.**

A statement by [**瑞銀**](https://dgw.tmarket.io/actors/01a1d49e-d995-7396-8810-d1e55c335b54). Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *私有化完成後，泰格醫藥擬收購中國內地非目標業務，初步估值約2.055億美元；生物分析及藥物代謝動力學(DMPK)等目標業務將出售予Charles River Laboratories，初步估值約4.7億美元；方達控股創辦人李松及相關信託或收購海外非目標業務，初步估值約8440萬美元。*

stockintelligencenewsPublished 2026-11-11 [ Read source](https://t.me/stockintelligencenews/5715728)

[**瑞銀 dossier **](https://dgw.tmarket.io/actors/01a1d49e-d995-7396-8810-d1e55c335b54)

## **Discussion**

## **Related claims**

[**After the privatization is completed, Tigermed plans to acquire Frontage's non-target business in mainland China at a preliminary valuation of about US$205.5 million; the target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; Frontage founder Li Song and related trusts may acquire the overseas non-target business at a preliminary valuation of about US$84.4 million.**瑞銀 · statement](https://dgw.tmarket.io/claims/01a1e74c-c295-7538-bc3f-a30a1cdabeb6) [**Tigermed announced it will participate in the privatization and business split of Frontage Holdings (01521) through its wholly-owned subsidiary Hong Kong Tigermed.**瑞銀 · statement](https://dgw.tmarket.io/claims/01a1e751-3011-7670-a475-41411a6a82cf) [**Tigermed announced it will participate in the privatization and business split of Frontage Holdings through its wholly-owned subsidiary Hong Kong Tigermed.**瑞銀 · statement](https://dgw.tmarket.io/claims/01a1e74c-c273-757f-bc30-201db5377830) [**Although divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.**瑞銀 · prediction](https://dgw.tmarket.io/claims/01a1e751-3094-73c5-92e4-9c2e1b97e4fa) [**Divesting Frontage may to some extent affect Tigermed's global layout and cross-border drug R&D competitiveness.**瑞銀 · prediction](https://dgw.tmarket.io/claims/01a1e74c-c2c2-7c6f-8bee-907f32b5c44d) [**If the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.**瑞銀 · prediction](https://dgw.tmarket.io/claims/01a1e751-306d-78f1-ac3c-2b57bdf9bbb3)

## **More claims by 瑞銀**

[**Although divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.**prediction](https://dgw.tmarket.io/claims/01a1e751-3094-73c5-92e4-9c2e1b97e4fa) [**Tigermed plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% possibly for dividends or share buybacks.**statement](https://dgw.tmarket.io/claims/01a1e751-3083-714b-9c7b-13200f21418b) [**If the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.**prediction](https://dgw.tmarket.io/claims/01a1e751-306d-78f1-ac3c-2b57bdf9bbb3) [**Frontage's laboratory network in the US and Europe is an important platform linking Tigermed to global markets; it supports the strategy of dual IND filings in China and the US and helps Chinese innovative drugmakers expand overseas, so divesting Frontage may affect Tigermed's global footprint and cross-border drug R&D competitiveness to some extent.**statement](https://dgw.tmarket.io/claims/01a1e751-3054-7ca0-a7ed-2ee97b0ffbc4) [**The cancellation price per Frontage Holdings share is HK$2.37, a 107.2% premium to the 360-day average share price, equivalent to about 91.6 times Frontage's 2025 price-to-earnings ratio.**statement](https://dgw.tmarket.io/claims/01a1e751-3025-769e-89ce-f5c5c2bcd583)

[All claims by 瑞銀](https://dgw.tmarket.io/claims?claimant_id=01a1d49e-d995-7396-8810-d1e55c335b54)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts — every claim cited to its public source. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1e751-3034-7cb6-8adc-d678204a44df#webpage","@type":"WebPage","description":"statement by 瑞銀, recorded recently — verbatim quote and source citation.","name":"After the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses… — 瑞銀 — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1e751-3034-7cb6-8adc-d678204a44df","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1e751-3034-7cb6-8adc-d678204a44df#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1e751-3034-7cb6-8adc-d678204a44df"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1e751-3034-7cb6-8adc-d678204a44df#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"After the privatization, Tigermed plans to acquire…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1e751-3034-7cb6-8adc-d678204a44df#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-11","isBasedOn":"https://t.me/stockintelligencenews/5715728","text":"私有化完成後，泰格醫藥擬收購中國內地非目標業務，初步估值約2.055億美元；生物分析及藥物代謝動力學(DMPK)等目標業務將出售予Charles River Laboratories，初步估值約4.7億美元；方達控股創辦人李松及相關信託或收購海外非目標業務，初步估值約8440萬美元。","url":"/claims/01a1e751-3034-7cb6-8adc-d678204a44df","spokenByCharacter":{"@type":"Person","name":"瑞銀","@id":"/actors/01a1d49e-d995-7396-8810-d1e55c335b54"}}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.
